The NUP58 antibody targets nucleoporin 58 (NUP58), a key component of the nuclear pore complex (NPC), a large protein assembly embedded in the nuclear envelope that regulates nucleocytoplasmic transport. NUP58. a member of the FG-nucleoporin family, contains phenylalanine-glycine (FG) repeats critical for mediating selective transport of macromolecules between the nucleus and cytoplasm. It interacts with other nucleoporins, such as NUP62 and NUP54. forming a dynamic subcomplex within the NPC’s central channel. Studies suggest NUP58 plays roles in mitotic progression, gene expression regulation, and maintaining nuclear integrity. Dysregulation of NUP58 has been linked to diseases, including certain cancers and autoimmune disorders. Antibodies against NUP58 are essential tools for investigating its localization, expression levels, and molecular interactions. They are widely used in techniques like immunofluorescence, Western blotting, and immunoprecipitation to study NPC architecture, transport mechanisms, and disease-related abnormalities. Commercially available NUP58 antibodies are typically raised in hosts like rabbits or mice, with validation in knockout models or siRNA-treated cells to confirm specificity. Researchers rely on these antibodies to explore NUP58’s contributions to cellular homeostasis and pathological conditions, bridging structural biology and translational medicine.